Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo

Journal of Experimental Medicine

Volumn 184, Issue 3, 1996, Pages 883-891

  Portanova, Joseph P ^a   Zhang, Yan ^a   Anderson, Gary D ^a   Hauser, Scott D ^a   Masferrer, Jaime L ^a   Seibert, Karen ^a   Gregory, Susan A ^a   Isakson, Peter C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRAGEENAN; INTERLEUKIN 6; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PROSTAGLANDIN E2;

ADJUVANT DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CONTROLLED STUDY; HYPERALGESIA; INFLAMMATION; MALE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN DETERMINATION; RAT; RNA ANALYSIS;

EID: 0029787626     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.184.3.883     Document Type: Article

References (40)

1. Garrison, J.C. 1990. Histamine, bradykinin, 5-hydroxytryptamine and their antagonists. In The Pharmacological Basis of Therapeutics. A. Gilman, T.W. Rall, A.S. Nies, and P. Taylor, editors. Pergamon Press, New York. 574-599.
2. Moncada, S., R.M. Palmer, and E.A. Higgs. 1991. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43:109-142.
3. Higgs, G.A., B. Henderson, S. Moncada, and J.A Salmon. 1985. The synthesis and inhibition of eicosanoids and inflammation. In Inflammatory Mediators. G.A. Higgs and T.J. Williams, editors. VCH Publishers, London. 19-37.
4. Needleman, P., J. Turk, B.A. Jakschik, A.R. Morrison, and J.B. Lefkowith. 1986. Arachidonic acid metabolism. Annu. Rev. Biochem. 55:69-102.
5. Smith, W.L. 1989. The eicosanoids and their biochemical mechanisms of action. Biochem. J. 259:315-324.
6. Vane, J.R., and R.M. Botting. 1994. Biological properties of cyclooxygenase products. In The Handbook of Immunopharmacology. F.M. Cunningham, editor. Academic Press, London. 61-97.
7. Williams, T.J.. and J. Morley. 1973. Prostaglandins as potentiators of increased vascular permeability in inflammation. Nature (Lond.). 246:215-217.
8. 2 and the vascular changes of inflammation. Br. J. Pharmacol. 65:517-524.
9. Moncada, S., S.H. Ferreira, and J.R. Vane. 1973. Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature (Lond.). 246:217-219.
10. Ferreira, S.H. 1972. Prostaglandins, aspirin-like drugs, and analgesia. Nature New Biol. 240:200-203.
11. 2. Prostaglandins. 16:31-37.
12. Davies, P., P.J. Bailey, and M. Goldenberg. 1984. The role of arachidonic acid oxygenation products in pain and inflammation. Annu. Rev. Immunol. 2:335-357.
13. Insel, P.A. 1990. Analgesic-antipyretics and antiinflammatory agents: drugs employed in the treatment of rheumatoid arthritis and gout. In The Pharmacolgical Basis of Therapeutics. A. Gilman, T.W. Rall, A.S. Nies, and P. Taylor, editors. Pergamon Press, New York. 638-681.
14. Raz, A., A. Wyche, and P. Needleman. 1989. Regulation of fibroblast cyclooxygenase synthesis by interleukin-1. J. Biol. Chem. 263:3022-3028.
15. O'Sullivan, G.M., F.H. Chilton, E.M. Huggins, Jr., and C.E. McCall. 1992. Lipopolysaccharide priming of alveolar macrophages for enhanced synthesis of eicosanoids involves induction of a novel prostaglandin H synthase. J. Biol. Chem. 267:14544-14550.
16. Masferrer, J.L., B.S. Zweifel, P. Manning, S. Hauser, K. Leahy, W. Smith, P. Isakson, and K. Seibert. 1994. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflaminatory and nonulcerogenic. Proc. Natl. Acad. Sci. USA. 91:3228-3232.
17. Futaki, N., K. Yoshikawa, Y. Hamasaka, I. Arai, S. Higuchi, H. Iizuka, and S. Otonio. 1993. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic efffects, which causes minimal stomach lesions. Gen. Pharmacol. 24:105-110.
18. Seibert, K., Y. Zhang, K. Leahy, S. Hauser, J. Masferrer, W. Perkins, L. Lee, and P. Isakson. 1994. Pharmacological and biochemical demonstration of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. USA. 91:12013-12017.
19. Higgs, G.A., S. Moncada, J.A. Salmon, and K. Seager. 1983. The source of thromboxane and prostaglandins in experimental inflammation. Br. J. Pharmacol. 79:863-868.
20. 2. J. Immunol. 155:4437-4444.
21. Winter, C.A., E.A. Risley, and G.W. Nuss. 1962. Carrageenaninduced edema in hind paw of the rat as an assay for antiinflammatory drugs. Proc. Soc. Exp. Biol. 111:544-552.
22. Hargreaves, K., R. Dubner, F. Brown, C. Flores, and J. Joris. 1988. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 32:77-88.
23. 1α in the rat paw. Prostaglandins. 16:153-161.
24. Otterness, I.G., and M.L. Bliven. 1985. Laboratory models for testing nonsteroidal antiinflammatory drugs. In Nonsteroidal Antiinflammatory Drugs. J. Lombardino, editor. John Wiley & Sons, Inc., New York. 111-252.
25. Anderson, G.D., S.D. Hauser, M.E. Bremmer, K.L. McGarity, P.C. Isakson, and S.A. Gregory. 1996. Selective inhibition of cyclooxygenase-2 reverses inflammation and expression of COX-2 and IL-6 in rat adjuvant arthritis. J. Clin. Invest. 97:2672-2679.
26. Willis, A.L. 1969. Release of histamine, kinin, and prostaglandins in carrageenan induced inflammation of the rat. In Prostaglandins, Peptides and Amines. P. Mantegazza and E.W. Horton, editors. Academic Press, London. 31-38.
27. Coleman, R.A., W.L. Smith, and S. Narumiya. 1994. International union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46:205-229.
28. 2 antagonists. J. Med. Chem. 36:3293-3299.
29. Smith, J.B., M.L. Ogletree, and A.M. Lefer. 1978. Antibodies which antagonize the effects of prostacyclin. Nature (Lond.). 274:64-65.
30. Bailly, S., B. Ferrua, and M. Fay. 1990. Differential regulation of IL 6, IL 1 alpha, IL 1 beta and TNF alpha production in LPS-stimulated human monocytes: role for cyclic AMP. Cytokine. 2:205-210.
31. Dendorfer, U., P. Oettegen, and T.A. Libermann. 1994. Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccahride. Mol. Cell Biol. 14:4443-4454.
32. 2 regulates macrophage-derived tumor necrosis factor gene expression. J. Biol. Chem. 263:5380-5384.
33. 2. J. Biol. Chem. 267:9443-9449.
34. Griswold, D.E., L.M. Hillegass, J.J. Breton, K.M. Esser, and J.L. Adams. 1993. Differentiation in vivo of classical non-steroidal antiinflammatory drugs from cytokine suppressive anti-inflammatory drugs and other pharmacological classes using mouse tumor necrosis alpha production. Drugs Exp. Clin. Res. 19:243-248.
35. Pettipher, E.R., and D.J. Wimberly. 1994. Cyclooxygenase inhibitors enhance tumor necrosis factor production and mortality in murine endotoxic shock. Cytokine. 6:500-505.
36. Goetzl, E.J., S. An, and W.L Smith. 1995. Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases. FASEB (Fed. Am. Soc. Exp. Biol.) J. 9:1051-1058.
37. Otto, J.C., and W.L. Smith. 1994. The orientation of prostaglandin endoperoxide synthases-1 and -2 in the endoplasmic reticulum. J. Biol. Chent. 269:19868-19875.
38. Morita, I., M. Schindler, M.K. Reiger, J.C. Otto, T. Hori, D.L. Dewitt, and W.L. Smith. 1995. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J. Biol. Chem. 270:10902-10908.
39. Reiger, M.A., J.C. Otto, D.L. Dewitt, and W.L. Smith. 1995. Localization of prostaglandin endoperoxide synthase-1 to the endoplasmic reticulum and nuclear envelope is independent of its C-terminal tetrapeptide-PTEL. Arch. Biochem. Biophys. 317:457-463.
40. 2 to the nuclear fraction upon macrophage activation. Biochem. Biophys. Res. Commun. 196:147-153.